Skip to content
20 November · 06:30 UTCFollow AstraZeneca by emailFollow

AZN · Pharma and healthcare · one day

AstraZeneca (AZN): news on Friday 20 November 2026

News from the 24 hours to Friday morning, 20 November 2026.

Tone of the day

+8.0strongly positive
Relevant headlines19of 24 read
Stories4grouped by event

What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.

Why it scored this way

Coverage was dominated by the FDA granting priority review to AstraZeneca's sonesitatug vedotin for gastric cancer, which is clearly positive. New collaborations in oncology and lupus added to the good tone, though a share price fall and cautious technical commentary tempered it.

What drove it

  • FDA priority review
  • Tempus AI partnership
  • share price fall

Around this day

DayToneHeadlines
Sat 14 Nov+5.539
Sun 15 Nov+7.59
Mon 16 Nov+4.56
Tue 17 Nov+9.745
Wed 18 Nov+7.029
Thu 19 Nov+5.523
Fri 20 Nov+8.019

4 stories · 19 headlines · strongest first

Pharma and healthcare on 20 NovemberFTSE 100 that day
ToneWhat the article reported, and why it scored that waySource
Sone-Ve, AstraZeneca's gastric cancer drug, receives priority review from the FDA +9.413 headlines today · The FDA accepted the BLA for sonesitatug vedotin with priority review for CLDN18.2-positive gastric cancers.
+10.0Regulator fast-tracks cancer drug backed by strong survival benefit.grafa.com (opens the article) ↗
+9.7Accelerated regulatory review granted for gastric cancer therapy.Seeking Alpha (opens the article) ↗
+9.5US regulator expedites review of cancer drug.London South East (opens the article) ↗
+9.5US regulator gives faster review to gastric cancer candidate.StreetInsider (opens the article) ↗
+9.5Gastric cancer medicine receives accelerated US regulatory review.Investing.com (opens the article) ↗
+9.5Official announcement of accelerated US review for gastric cancer drug.Yahoo Finance (opens the article) ↗
+9.3Quick regulatory review for targeted gastric cancer treatment.FirstWord Pharma (opens the article) ↗
+9.3Gastric cancer drug obtains accelerated US regulatory review.Securities.io (opens the article) ↗
+9.3Company announces accelerated US review of its application.TradingView (opens the article) ↗
+9.3Share-focused coverage of accelerated regulatory review for cancer drug.AD HOC NEWS (opens the article) ↗
+9.2Licence application accepted for expedited US assessment.The Pharma Letter (opens the article) ↗
+9.2Licence application accepted with accelerated review status.TipRanks (opens the article) ↗
+8.3Company pursuing American approval for gastric cancer treatment.GenomeWeb (opens the article) ↗
AstraZeneca pledges $200m to Tempus AI as their agreement is extended +4.62 headlines today · 12 in all, since 19 November · AstraZeneca extended its Tempus AI partnership with a $200m commitment.
+5.8Extended data and AI oncology partnership with sizeable financial commitment.Oncodaily (opens the article) ↗
+5.0Partnership extended with large spending pledge; analyst valuation caveat.TradingView (opens the article) ↗
AstraZeneca share price moves −1.92 headlines today · 4 in all, since 19 November · Pieces report AstraZeneca down 2.51% and downside momentum.
−5.8Share price dropped notably during the trading day.Global Banking & Finance Review (opens the article) ↗
−4.2Technical view says weak price momentum continues, though support holds.Traders Union (opens the article) ↗
AstraZeneca collaborates with Lupus Research Alliance +5.52 headlines today · AstraZeneca has entered a partnership with Lupus Research Alliance and Lupus Therapeutics to develop lupus drugs.
+5.5New research tie-up aimed at developing lupus treatments.Contract Pharma (opens the article) ↗
+5.5Lupus organisations partner with company on drug development.PR Newswire (opens the article) ↗

Each article has its own score. The lines are our own summary; follow the source link to read the article itself.

Follow by email

A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.

How it works. Every morning an AI model reads the UK business news about each FTSE 100 company and scores how good or bad it is for the company, from −10 to +10. Pages update by about 07:45 UK time.

Not investment advice. MarketFrame rates the tone of news coverage. It is general information, not a recommendation to buy or sell anything. The scores are not share-price data or forecasts: a good score doesn't mean a share will rise, and a bad one doesn't mean it will fall.

Data to 06:30 UTC, 20 November · 852 headlines · 87 companiesMade by Adapt Progress Evolve Limited, a UK company · Privacy · Terms · Who we are · RSS · API · llms.txt